This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Hims & Hers Health (HIMS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Hims & Hers Health, Inc. (HIMS) and TransMedics (TMDX) have performed compared to their sector so far this year.
Here's How STERIS (STE) is Placed Ahead of Q1 Earnings
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2025 results are likely to reflect the positives of the normalization of the Healthcare backlog, along with a core focus on pharma and MedTech.
Strong CAG Sales to Aid IDEXX Laboratories' (IDXX) Q2 Earnings
by Zacks Equity Research
IDEXX Laboratories' (IDXX) second-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.
TransMedics (TMDX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
TransMedics (TMDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
TransMedics (TMDX) Just Reclaimed the 20-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Are You Looking for a Top Momentum Pick? Why TransMedics (TMDX) is a Great Choice
by Zacks Equity Research
Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Trending Stock TransMedics Group, Inc. (TMDX) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching TransMedics (TMDX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Will TransMedics (TMDX) Gain on Rising Earnings Estimates?
by Zacks Equity Research
TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens
by Zacks Equity Research
Illumina (ILMN) surpasses expectations in the first quarter in a challenging global macroeconomic environment.
Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View
by Zacks Equity Research
Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
TransMedics Group, Inc. (TMDX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
TransMedics (TMDX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is TransMedics (TMDX) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in TransMedics (TMDX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
TransMedics (TMDX) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 800% and 16.24%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
How You Should Play Hologic (HOLX) Ahead of Q2 Earnings
by Riya Anand
Hologic's (HOLX) second-quarter 2024 earnings will likely reflect gains from the GYN surgical business and the growing adoption of Panther instruments.
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
by Zacks Equity Research
Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.
Should Lifeward (LFWD) be in Your Portfolio Ahead of Q1 Earnings?
by Moumi Mondal
Lifeward's (LFWD) first-quarter 2024 results are expected to reflect the benefits of several milestone achievements from last year.
Exploring Analyst Estimates for TransMedics (TMDX) Q1 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for TransMedics (TMDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
ResMed (RMD) Q3 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed's (RMD) fiscal 2024 third-quarter performance reflects another strong period of execution across the entire business, resulting in impressive top and bottom-line growth.
Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View
by Zacks Equity Research
Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.
TransMedics (TMDX) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the latest trading session, TransMedics (TMDX) closed at $88.88, marking a -1.9% move from the previous day.
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.
LivaNova (LIVN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect
by Zacks Equity Research
Strong global new customer starts fueled by the ongoing Omnipod 5 demand are expected to significantly benefit Insulet's (PODD) first-quarter performance.